Aarti Drugs Limited witnessed a 15% surge in its stock price after receiving the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA). The EIR pertains to the company’s API manufacturing facility at Plot No. E-22, MIDC, Tarapur, Maharashtra.
The inspection, now classified as “Voluntary Action Indicated” (VAI), signifies minimal compliance concerns with Current Good Manufacturing Practices (CGMP). This positive development confirms the closure of the inspection and reinforces Aarti Drugs’ commitment to global regulatory standards and quality manufacturing.
Aarti Drugs shares opened at ₹424.00 today, reaching a high of ₹497.60 and a low of ₹421.15. The stock’s 52-week range is ₹419.55 to ₹635.00.
As of 3:18 pm, Aarti Drug shares were trading 13.80% higher at Rs 482.00 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
